Identifying systemic safety signals following intravitreal bevacizumab: systematic review of the literature and the Canadian Adverse Drug Reaction Database

2010 ◽  
Vol 45 (3) ◽  
pp. 231-238 ◽  
Author(s):  
Jonathan A. Micieli ◽  
Andrew Micieli ◽  
Andrew F. Smith
Keyword(s):  
Systematic Review ◽  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Adverse Drug Reaction Database ◽  
Intravitreal Bevacizumab ◽  
Review Of The Literature ◽  
Safety Signals

Strategies to Improve Adverse Drug Reaction Reporting: A Critical and Systematic Review

Drug Safety ◽  
2013 ◽  
Vol 36 (5) ◽  
pp. 317-328 ◽  
Author(s):  
Cristian Gonzalez-Gonzalez ◽  
Elena Lopez-Gonzalez ◽  
Maria T. Herdeiro ◽  
Adolfo Figueiras
Keyword(s):  
Systematic Review ◽  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Adverse Drug Reaction Reporting ◽  
Reaction Reporting

scholarly journals Aripiprazole as a risk factor for impulse control disorders: a systematic review

BJPsych Open ◽  
2021 ◽  
Vol 7 (S1) ◽  
pp. S300-S301
Author(s):  
Benjamin Williams ◽  
Benjamin Williams ◽  
Kishen Neelam ◽  
Saumya Singh
Keyword(s):  
Systematic Review ◽  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Dopamine Agonist ◽  
Impulse Control ◽  
Bipolar Affective Disorder ◽  
Impulse Control Disorders ◽  
Risk Of Bias ◽  
Potential Association ◽  
Increased Risk

AimsAripiprazole is an anti-psychotic medication widely used for bipolar affective disorder and depression. It's primary mechanism of action is as a partial dopamine agonist. Aripiprazole's effect on dopamine signalling in the mesolimbic and mesocortical pathways may lead to impulse control disorders, as seen with other dopamine agonist medications. Aripiprazole is often chosen by prescribers because of its favourable side effect profile. There is a need to synthesise the available epidemiological literature on the potential association between aripiprazole use and impulse control disorders. This is needed to inform patients and prescribers of the best available evidence regarding this potential association. Our aim is to conduct a systematic review of the available non case-study evidence on the potential association between aripiprazole and impulse control disorders.MethodDatabases were searched using MEDLINE, PsychINFO, EMBASE, Cochrane Clinical Trials and Web of science. All studies from no earliest date to December 2020 were included; adult patients with a severe and enduring mental illness prescribed antipsychotic medication were included. Cinician diagnosis, structured interview diagnosis, and interviewer or self-completion questionnaires were used to measure prevalence. The study designs included were experimental designs, cohort study, cross-sectional survey and administrative databases. Exclusion criteria being those with traumatic brain injury, psychosis secondary to autoimmune, iatrogenic, chromosomal or metabolic disorder, those with Learning disability or Autistic Spectrum disorders. studies with majority of participants <18yrs. Those who were on other antipsychotic medications in addition to Aripiprazole, were excluded. To ensure quality assurance, we used ROBINS-I tool and GRADE assessment to measure the risk of bias.Result240 records were retrieved, 187 after duplicates were removed. 8 full text articles were assessed for eligibility, of which 4 were included in the qualitative synthesis. 2 studies were analyses of spontaneous adverse drug reaction reporting systems and 2 of health insurance claims databases. All 4 studies found aripiprazole to be associated with greater risk of impulse control disorders. The single study which compared directly with other antipsychotics had a much smaller effect size. Study heterogeneity precluded meta-analysis. All studies were at high risk of bias. The quality of evidence is very low.ConclusionThe available evidence is consistent with the existing warnings regarding increased risk of impulse control disorders in patients prescribed aripiprazole. Clinicians may wish to monitor for this adverse drug reaction. Further research which can account for potential confounders, examines specific impulse control disorders and which is less susceptible to detection and ascertainment biases is required.

scholarly journals Causes for the underreporting of adverse drug events by health professionals: a systematic review

2014 ◽  
Vol 48 (4) ◽  
pp. 739-747 ◽  
Author(s):  
Fabiana Rossi Varallo ◽  
Synara de Oliveira Paim Guimarães ◽  
Samir Antonio Rodrigues Abjaude ◽  
Patricia de Carvalho Mastroianni
Keyword(s):  
Systematic Review ◽  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Drug Use ◽  
Continuing Education ◽  
Health Professionals ◽  
Adverse Drug Events

Objective: Identifying the main causes for underreporting of Adverse Drug Reaction (ADR) by health professionals. Method: A systematic review carried out in the following databases: LILACS, PAHO, SciELO, EMBASE and PubMed in the period between 1992 and 2012. Descriptors were used in the search for articles, and the identified causes of underreporting were analyzed according to the classification of Inman. Results: In total, were identified 149 articles, among which 29 were selected. Most studies were carried out in hospitals (24/29) for physicians (22/29), and pharmacists (10/29). The main causes related to underreporting were ignorance (24/29), insecurity (24/29) and indifference (23/29). Conclusion: The data show the eighth sin in underreporting, which is the lack of training in pharmacovigilance. Therefore, continuing education can increase adherence of professionals to the service and improve knowledge and communication of risks due to drug use.


Sign in / Sign up

Export Citation Format

Share Document